Table 1. Proteomic signature of protein level changes following GSK2141795 treatment across xenografts and cell lines as described in Materials and Methods.
| Proteins increased on GSK2141795 treatment | FoldChange | P-value | Adj P-value |
| Akt_pS473 | 1.327855 | 0.000100 | 0.003125 |
| Akt_pT308 | 2.181444 | 0.000100 | 0.003125 |
| p38_pT180_Y182 | 1.144112 | 0.000100 | 0.003125 |
| STAT5_alpha | 1.304476 | 0.000100 | 0.003125 |
| Bim | 1.248445 | 0.001990 | 0.049760 |
| IGF_1R_beta | 1.144254 | 0.004482 | 0.093367 |
| YAP_pS127 | 1.148339 | 0.006125 | 0.109371 |
| GSK3_alpha_beta_pS21_S9 | 0.421782 | 0.008931 | 0.139550 |
| MAPK_pT202_Y204 | 0.968154 | 0.014187 | 0.197044 |
| AR | 1.081206 | 0.017242 | 0.215530 |
| YB_1 | 1.177568 | 0.031214 | 0.354700 |
| Proteins decreased on GSK2141795 treatment | FoldChange | P-value | Adj P-value |
| Cyclin_B1 | 0.672057 | 0.000100 | 0.003950 |
| S6_pS235_S236 | 0.137526 | 0.000100 | 0.003950 |
| S6_pS240_S244 | 0.194702 | 0.000100 | 0.003950 |
| Caspase_7_cleaved_D198 | 0.797813 | 0.000126 | 0.003950 |
| Rb_pS807_S811 | 0.709457 | 0.000175 | 0.004380 |
| EGFR | 0.799100 | 0.000595 | 0.012400 |
| 53BP1 | 0.875146 | 0.001762 | 0.031471 |
| IGFBP2 | 0.896407 | 0.002767 | 0.043238 |
| NF2 | 0.821243 | 0.005116 | 0.071056 |
| 4E.BP1_pS65 | 0.713764 | 0.010503 | 0.131290 |
| Tuberin | 0.788187 | 0.011787 | 0.132717 |
| ACC1 | 0.864443 | 0.012741 | 0.132717 |
| EGFR_pY992 | 0.961440 | 0.021906 | 0.210638 |
| VEGFR2 | 0.897841 | 0.029226 | 0.248513 |
| Fibronectin | 0.807220 | 0.030147 | 0.248513 |
| PRAS40_pT246 | 0.668444 | 0.031810 | 0.248513 |
| ACC_pS79 | 0.858526 | 0.035321 | 0.259712 |
A cut-off of p<0.05 in the RankProd meta-analysis was applied.